Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 264

1.

Tachikawa project for prevention of posttraumatic stress disorder with polyunsaturated fatty acid (TPOP): study protocol for a randomized controlled trial.

Matsuoka Y, Nishi D, Yonemoto N, Hamazaki K, Matsumura K, Noguchi H, Hashimoto K, Hamazaki T.

BMC Psychiatry. 2013 Jan 5;13:8. doi: 10.1186/1471-244X-13-8.

2.

Docosahexaenoic acid for selective prevention of posttraumatic stress disorder among severely injured patients: a randomized, placebo-controlled trial.

Matsuoka Y, Nishi D, Hamazaki K, Yonemoto N, Matsumura K, Noguchi H, Hashimoto K, Hamazaki T.

J Clin Psychiatry. 2015 Aug;76(8):e1015-22. doi: 10.4088/JCP.14m09260.

3.
4.

Serum pro-BDNF/BDNF as a treatment biomarker for response to docosahexaenoic acid in traumatized people vulnerable to developing psychological distress: a randomized controlled trial.

Matsuoka Y, Nishi D, Tanima Y, Itakura M, Kojima M, Hamazaki K, Noguchi H, Hamazaki T.

Transl Psychiatry. 2015 Jul 7;5:e596. doi: 10.1038/tp.2015.89.

PMID:
26151924
5.

The mothers, Omega-3 and mental health study.

Mozurkewich E, Chilimigras J, Klemens C, Keeton K, Allbaugh L, Hamilton S, Berman D, Vazquez D, Marcus S, Djuric Z, Vahratian A.

BMC Pregnancy Childbirth. 2011 Jun 22;11:46. doi: 10.1186/1471-2393-11-46.

6.

Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials.

Kwak SM, Myung SK, Lee YJ, Seo HG; Korean Meta-analysis Study Group.

Arch Intern Med. 2012 May 14;172(9):686-94. doi: 10.1001/archinternmed.2012.262. Review.

PMID:
22493407
7.

The efficacy of omega-3 supplementation for major depression: a randomized controlled trial.

Lespérance F, Frasure-Smith N, St-André E, Turecki G, Lespérance P, Wisniewski SR.

J Clin Psychiatry. 2011 Aug;72(8):1054-62. doi: 10.4088/JCP.10m05966blu. Epub 2010 Jun 15.

PMID:
20584525
9.

Potential role of brain-derived neurotrophic factor in omega-3 Fatty Acid supplementation to prevent posttraumatic distress after accidental injury: an open-label pilot study.

Matsuoka Y, Nishi D, Yonemoto N, Hamazaki K, Hamazaki T, Hashimoto K.

Psychother Psychosom. 2011;80(5):310-2. doi: 10.1159/000322980. Epub 2011 Jun 30. No abstract available.

10.

Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial.

Carney RM, Freedland KE, Rubin EH, Rich MW, Steinmeyer BC, Harris WS.

JAMA. 2009 Oct 21;302(15):1651-7. doi: 10.1001/jama.2009.1487.

11.

ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial.

Torkildsen O, Wergeland S, Bakke S, Beiske AG, Bjerve KS, Hovdal H, Midgard R, Lilleås F, Pedersen T, Bjørnarå B, Dalene F, Kleveland G, Schepel J, Olsen IC, Myhr KM.

Arch Neurol. 2012 Aug;69(8):1044-51. doi: 10.1001/archneurol.2012.283.

PMID:
22507886
13.

Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial.

Dunlop BW, Rothbaum BO, Binder EB, Duncan E, Harvey PD, Jovanovic T, Kelley ME, Kinkead B, Kutner M, Iosifescu DV, Mathew SJ, Neylan TC, Kilts CD, Nemeroff CB, Mayberg HS.

Trials. 2014 Jun 21;15:240. doi: 10.1186/1745-6215-15-240.

14.

Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers.

Buydens-Branchey L, Branchey M, Hibbeln JR.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):568-75. Epub 2007 Nov 1.

15.

Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial.

Janczyk W, Socha P, Lebensztejn D, Wierzbicka A, Mazur A, Neuhoff-Murawska J, Matusik P.

BMC Pediatr. 2013 May 23;13:85. doi: 10.1186/1471-2431-13-85.

16.

Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.

Amminger GP, Schäfer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE.

Arch Gen Psychiatry. 2010 Feb;67(2):146-54. doi: 10.1001/archgenpsychiatry.2009.192.

PMID:
20124114
17.

Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.

Irish A, Dogra G, Mori T, Beller E, Heritier S, Hawley C, Kerr P, Robertson A, Rosman J, Paul-Brent PA, Starfield M, Polkinghorne K, Cass A.

BMC Nephrol. 2009 Jan 21;10:1. doi: 10.1186/1471-2369-10-1.

18.

Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods.

Pawełczyk T, Grancow M, Kotlicka-Antczak M, Trafalska E, Gębski P, Szemraj J, Żurner N, Pawełczyk A.

BMC Psychiatry. 2015 May 2;15:97. doi: 10.1186/s12888-015-0473-2.

19.

The Infant Fish Oil Supplementation Study (IFOS): design and research protocol of a double-blind, randomised controlled n--3 LCPUFA intervention trial in term infants.

Meldrum SJ, D'Vaz N, Dunstan J, Mori TA, Prescott SL.

Contemp Clin Trials. 2011 Sep;32(5):771-8. doi: 10.1016/j.cct.2011.05.019. Epub 2011 Jun 22.

PMID:
21718804
20.

Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.

Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J.

Arch Neurol. 2006 Oct;63(10):1402-8.

PMID:
17030655
Items per page

Supplemental Content

Write to the Help Desk